Regulation of the p53 response and its relationship to cancer

Biochemical Journal

Volumn 469, Issue 3, 2015, Pages 325-346

  Meek, David W ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

MDM2; p53; Post translational modification; Signalling; Tumour suppressor

Indexed keywords

PROTEIN MDM2; PROTEIN P53; SERINE; SERINE 15; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACETYLATION; CANCER INHIBITION; CANCER THERAPY; DNA DAMAGE; GAIN OF FUNCTION MUTATION; HUMAN; MUTANT; NEOPLASM; NONHUMAN; ONCOGENE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STIMULUS; STRESS; ANIMAL; GENETICS; METABOLISM;

MURINAE;

ANIMALS; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84938633240     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20150517     Document Type: Review

References (295)

1. Beckerman, R. and Prives, C. (2010) Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol. 2, a000935 CrossRef PubMed
2. Lane, D. and Levine, A. (2010) p53 research: the past thirty years and the next thirty years. Cold Spring Harb. Perspect. Biol. 2, a000893 PubMed
3. Riley, T., Sontag, E., Chen, P. and Levine, A. (2008) Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9, 402-412 CrossRef PubMed
4. Vousden, K.H. and Prives, C. (2009) Blinded by the light: the growing complexity of p53. Cell 137, 413-431 CrossRef PubMed
5. Hu, W., Feng, Z. and Levine, A.J. (2012) The regulation of multiple p53 stress responses is mediated through MDM2. Genes Cancer 3, 199-208 CrossRef PubMed
6. Vousden, K.H. and Lane, D.P. (2007) p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8, 275-283 CrossRef PubMed
7. Teodoro, J.G., Evans, S.K. and Green, M.R. (2007) Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J. Mol. Med. 85, 1175-1186 CrossRef PubMed
8. Lane, D.P. (1992) Cancer: p53, guardian of the genome. Nature 358, 15-16 CrossRef PubMed
9. Levine, A.J., Tomasini, R., McKeon, F.D., Mak, T.W. and Melino, G. (2011) The p53 family: guardians of maternal reproduction. Nat. Rev. Mol. Cell Biol. 12, 259-265 CrossRef PubMed
10. Aloni-Grinstein, R., Shetzer, Y., Kaufman, T. and Rotter, V. (2014) p53: the barrier to cancer stem cell formation. FEBS Lett. 588, 2580-2589 CrossRef PubMed
11. Solozobova, V. and Blattner, C. (2011) p53 in stem cells. World J. Biol. Chem. 2, 202-214 CrossRef PubMed
12. Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M. and Scrable, H. (2004) Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18, 306-319 CrossRef PubMed
13. Tyner, S.D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C. et al. (2002) p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45-53 CrossRef PubMed
14. Cui, R., Widlund, H.R., Feige, E., Lin, J.Y., Wilensky, D.L., Igras, V.E., D'Orazio, J., Fung, C.Y., Schanbacher, C.F., Granter, S.R. and Fisher, D.E. (2007) Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 128, 853-864 CrossRef PubMed
15. Komarova, E.A., Krivokrysenko, V., Wang, K., Neznanov, N., Chernov, M.V., Komarov, P.G., Brennan, M.L., Golovkina, T.V., Rokhlin, O.W., Kuprash, D.V. et al. (2005) p53 is a suppressor of inflammatory response in mice. FASEB J. 19, 1030-1032 PubMed
16. Liu, G., Park, Y.J., Tsuruta, Y., Lorne, E. and Abraham, E. (2009) p53 attenuates lipopolysaccharide-induced NF-κB activation and acute lung injury. J. Immunol. 182, 5063-5071 CrossRef PubMed
17. Feng, Z. and Levine, A.J. (2010) The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 20, 427-434 CrossRef PubMed
18. Vousden, K.H. and Ryan, K.M. (2009) p53 and metabolism. Nat. Rev. Cancer 9, 691-700 CrossRef PubMed
19. Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A.J. et al. (2013) Tumour-associated mutant p53 drives the Warburg effect. Nat. Commun. 4, 2935 PubMed
20. Gudkov, A.V. and Komarova, E.A. (2010) Pathologies associated with the p53 response. Cold Spring Harb. Perspect. Biol. 2, a001180 CrossRef PubMed
21. Bretaud, S., Allen, C., Ingham, P.W. and Bandmann, O. (2007) p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J. Neurochem. 100, 1626-1635 PubMed
22. Checler, F. and Alves da Costa, C. (2014) Interplay between parkin and p53 governs a physiological homeostasis that is disrupted in Parkinson's disease and cerebral cancer. Neurodegener. Dis. 13, 118-121 CrossRef PubMed
23. Illuzzi, J., Yerkes, S., Parekh-Olmedo, H. and Kmiec, E.B. (2009) DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates. J. Neurosci. Res. 87, 733-747 CrossRef PubMed
24. Bae, B.I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S.D., Moran, T.H., Montell, C., Ross, C.A. et al. (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29-41 CrossRef PubMed
25. Illuzzi, J.L., Vickers, C.A. and Kmiec, E.B. (2011) Modifications of p53 and the DNA damage response in cells expressing mutant form of the protein huntingtin. J. Mol. Neurosci. 45, 256-268 CrossRef PubMed
26. 46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin. Proc. Natl. Acad. Sci. U.S.A. 108, 17979-17984 CrossRef PubMed
27. Checler, F. and Alves da Costa, C. (2014) p53 in neurodegenerative diseases and brain cancers. Pharmacol. Ther. 142, 99-113 CrossRef PubMed
28. Matsusaka, H., Ide, T., Matsushima, S., Ikeuchi, M., Kubota, T., Sunagawa, K., Kinugawa, S. and Tsutsui, H. (2006) Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice. Cardiovasc. Res. 70, 457-465 CrossRef PubMed
29. Georgiev, P., Dahm, F., Graf, R. and Clavien, P.A. (2006) Blocking the path to death: anti-apoptotic molecules in ischemia/reperfusion injury of the liver. Curr. Pharm. Des. 12, 2911-2921 CrossRef PubMed
30. Fiskum, G., Rosenthal, R.E., Vereczki, V., Martin, E., Hoffman, G.E., Chinopoulos, C. and Kowaltowski, A. (2004) Protection against ischemic brain injury by inhibition of mitochondrial oxidative stress. J. Bioenerg. Biomembr. 36, 347-352 CrossRef PubMed
31. Dagher, P.C. (2004) Apoptosis in ischemic renal injury: roles of GTP depletion and p53. Kidney Int. 66, 506-509 CrossRef PubMed
32. Shinozaki, S., Chang, K., Sakai, M., Shimizu, N., Yamada, M., Tanaka, T., Nakazawa, H., Ichinose, F., Yamada, Y., Ishigami, A. et al. (2014) Inflammatory stimuli induce inhibitory S-nitrosylation of the deacetylase SIRT1 to increase acetylation and activation of p53 and p65. Sci. Signal. 7, ra106 PubMed
33. Campbell, H.G., Mehta, R., Neumann, A.A., Rubio, C., Baird, M., Slatter, T.L. and Braithwaite, A.W. (2013) Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD). Oncogene 32, 827-836 CrossRef PubMed
34. Anderson, C.W. and Appella, E. (2010) Signaling to the p53 tumor suppressor through pathways activated by genotoxic and non-genotoxic stresses. In Handbook of Cell Signaling (Bradshaw, R.A. and Dennis, E.A., eds), pp. 237-247, Elsevier, Amsterdam
35. Appella, E. and Anderson, C.W. (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268, 2764-2772 CrossRef PubMed
36. Carr, S.M., Munro, S. and La Thangue, N.B. (2012) Lysine methylation and the regulation of p53. Essays Biochem. 52, 79-92 CrossRef PubMed
37. Dai, C. and Gu, W. (2010) p53 post-translational modification: deregulated in tumorigenesis. Trends Mol. Med. 16, 528-536 CrossRef PubMed
38. Dotsch, V., Bernassola, F., Coutandin, D., Candi, E. and Melino, G. (2010) p63 and p73, the ancestors of p53. Cold Spring Harb. Perspect. Biol. 2, a004887 CrossRef PubMed
39. Flores, E.R., Sengupta, S., Miller, J.B., Newman, J.J., Bronson, R., Crowley, D., Yang, A., McKeon, F. and Jacks, T. (2005) Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7, 363-373 CrossRef PubMed
40. Marcel, V., Dichtel-Danjoy, M.L., Sagne, C., Hafsi, H., Ma, D., Ortiz-Cuaran, S., Olivier, M., Hall, J., Mollereau, B., Hainaut, P. and Bourdon, J.C. (2011) Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ. 18, 1815-1824 CrossRef PubMed
41. Bourdon, J.C. (2014) p53 isoforms change p53 paradigm. Mol. Cell. Oncol. 1, e969136 CrossRef
42. Chen, Z., Trotman, L.C., Shaffer, D., Lin, H.K., Dotan, Z.A., Niki, M., Koutcher, J.A., Scher, H.I., Ludwig, T., Gerald, W. et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 CrossRef PubMed
43. Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K. and McMahon, M. (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21, 379-384 CrossRef PubMed
44. Eischen, C.M., Weber, J.D., Roussel, M.F., Sherr, C.J. and Cleveland, J.L. (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13, 2658-2669 CrossRef PubMed
45. Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P. and Olivier, M. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28, 622-629 CrossRef PubMed
46. Brown, C.J., Lain, S., Verma, C.S., Fersht, A.R. and Lane, D.P. (2009) Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9, 862-873 CrossRef PubMed
47. Martins, C.P., Brown-Swigart, L. and Evan, G.I. (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 CrossRef PubMed
48. Ventura, A., Kirsch, D.G., McLaughlin, M.E., Tuveson, D.A., Grimm, J., Lintault, L., Newman, J., Reczek, E.E., Weissleder, R. and Jacks, T. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 CrossRef PubMed
49. Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C. and Lowe, S.W. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 CrossRef PubMed
50. Khoo, K.H., Verma, C.S. and Lane, D.P. (2014) Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 13, 217-236 CrossRef PubMed
51. Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A.J., Barradas, M., Benguría, A., Zaballos, A., Flores, J.M., Barbacid, M. et al. (2005) Tumour biology: senescence in premalignant tumours. Nature 436, 642 CrossRef PubMed
52. Cosme-Blanco, W., Shen, M.F., Lazar, A.J., Pathak, S., Lozano, G., Multani, A.S. and Chang, S. (2007) Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 8, 497-503 CrossRef PubMed
53. Schmitt, C.A., McCurrach, M.E., de Stanchina, E., Wallace-Brodeur, R.R. and Lowe, S.W. (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670-2677 CrossRef PubMed
54. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T. and Van Dyke, T. (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711 CrossRef PubMed
55. Brady, C.A., Jiang, D., Mello, S.S., Johnson, T.M., Jarvis, L.A., Kozak, M.M., Kenzelmann Broz, D., Basak, S., Park, E.J., McLaughlin, M.E. et al. (2011) Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145, 571-583 CrossRef PubMed
56. Jiang, D., Brady, C.A., Johnson, T.M., Lee, E.Y., Park, E.J., Scott, M.P. and Attardi, L.D. (2011) Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc. Natl. Acad. Sci. U.S.A. 108, 17123-17128 CrossRef PubMed
57. Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R. and Gu, W. (2012) Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269-1283 CrossRef PubMed
58. Valente, L.J., Gray, D.H., Michalak, E.M., Pinon-Hofbauer, J., Egle, A., Scott, C.L., Janic, A. and Strasser, A. (2013) p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 3, 1339-1345 CrossRef PubMed
59. Mirza, A., Wu, Q., Wang, L., McClanahan, T., Bishop, W.R., Gheyas, F., Ding, W., Hutchins, B., Hockenberry, T., Kirschmeier, P. et al. (2003) Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22, 3645-3654 CrossRef PubMed
60. Muller, P.A. and Vousden, K.H. (2014) Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304-317 CrossRef PubMed
61. Oren, M. and Rotter, V. (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2, a001107 CrossRef PubMed
62. Freed-Pastor, W.A. and Prives, C. (2012) Mutant p53: one name, many proteins. Genes Dev. 26, 1268-1286 CrossRef PubMed
63. Goh, A.M., Coffill, C.R. and Lane, D.P. (2011) The role of mutant p53 in human cancer. J. Pathol. 223, 116-126 CrossRef PubMed
64. Muller, P.A. and Vousden, K.H. (2013) p53 mutations in cancer. Nat. Cell Biol. 15, 2-8 CrossRef PubMed
65. Lang, G.A., Iwakuma, T., Suh, Y.A., Liu, G., Rao, V.A., Parant, J.M., Valentin-Vega, Y.A., Terzian, T., Caldwell, L.C., Strong, L.C. et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872 CrossRef PubMed
66. Olive, K.P., Tuveson, D.A., Ruhe, Z.C., Yin, B., Willis, N.A., Bronson, R.T., Crowley, D. and Jacks, T. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860 CrossRef PubMed
67. Song, H., Hollstein, M. and Xu, Y. (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat. Cell Biol. 9, 573-580 CrossRef PubMed
68. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674 CrossRef PubMed
69. Brooks, C.L. and Gu, W. (2006) p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307-315 CrossRef PubMed
70. Jones, S.N., Roe, A.E., Donehower, L.A. and Bradley, A. (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208 CrossRef PubMed
71. Montes de Oca Luna, R., Wagner, D.S. and Lozano, G. (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206 CrossRef PubMed
72. Ringshausen, I., O'Shea, C.C., Finch, A.J., Swigart, L.B. and Evan, G.I. (2006) Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10, 501-514 CrossRef PubMed
73. Rodriguez, M.S., Desterro, J.M., Lain, S., Lane, D.P. and Hay, R.T. (2000) Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 20, 8458-8467 CrossRef PubMed
74. Feng, L., Lin, T., Uranishi, H., Gu, W. and Xu, Y. (2005) Functional analysis of the roles of posttranslational modifications at p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 25, 5389-5395 CrossRef PubMed
75. Krummel, K.A., Lee, C.J., Toledo, F. and Wahl, G. (2005) The C-terminal lysines fine-tune p53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. U.S.A. 102, 10188-10193 CrossRef PubMed
76. Li, M., Brooks, C.L., Wu-Baer, F., Chen, D., Baer, R. and Gu, W. (2003) Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302, 1972-1975 CrossRef PubMed
77. Wu, X., Bayle, J.H., Olson, D. and Levine, A.J. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132 CrossRef PubMed
78. INK4a loss. Genes Dev. 22, 1337-1344 CrossRef PubMed
79. Guo, L., Liew, H.P., Camus, S., Goh, A.M., Chee, L.L., Lunny, D.P., Lane, E.B. and Lane, D.P. (2013) Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish. Oncogene 32, 4009-4016 CrossRef PubMed
80. Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J. and Pavletich, N.P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 CrossRef PubMed
81. Kulikov, R., Winter, M. and Blattner, C. (2006) Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J. Biol. Chem. 281, 28575-28583 CrossRef PubMed
82. Shimizu, H., Burch, L.R., Smith, A.J., Dornan, D., Wallace, M., Ball, K.L. and Hupp, T.R. (2002) The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 277, 28446-28458 CrossRef PubMed
83. Wallace, M., Worrall, E., Pettersson, S., Hupp, T.R. and Ball, K.L. (2006) Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 23, 251-263 CrossRef PubMed
84. Yu, G.W., Rudiger, S., Veprintsev, D., Freund, S., Fernandez-Fernandez, M.R. and Fersht, A.R. (2006) The central region of HDM2 provides a second binding site for p53. Proc. Natl. Acad. Sci. U.S.A. 103, 1227-1232 CrossRef PubMed
85. Biderman, L., Manley, J.L. and Prives, C. (2012) Mdm2 and MdmX as regulators of gene expression. Genes Cancer 3, 264-273 CrossRef PubMed
86. Marine, J.C., Dyer, M.A. and Jochemsen, A.G. (2007) MDMX: from bench to bedside. J. Cell Sci. 120, 371-378 CrossRef PubMed
87. Toledo, F. and Wahl, G.M. (2007) MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int. J. Biochem. Cell Biol. 39, 1476-1482 CrossRef PubMed
88. Wade, M., Li, Y.C. and Wahl, G.M. (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13, 83-96 CrossRef PubMed
89. Wang, X., Wang, J. and Jiang, X. (2011) MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J. Biol. Chem. 286, 23725-23734 CrossRef PubMed
90. Kawai, H., Lopez-Pajares, V., Kim, M.M., Wiederschain, D. and Yuan, Z.M. (2007) RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res. 67, 6026-6030 CrossRef PubMed
91. Chen, L., Gilkes, D.M., Pan, Y., Lane, W.S. and Chen, J. (2005) ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 24, 3411-3422 CrossRef PubMed
92. Fang, S., Jensen, J.P., Ludwig, R.L., Vousden, K.H. and Weissman, A.M. (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945-8951 CrossRef PubMed
93. Honda, R. and Yasuda, H. (2000) Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19, 1473-1476 CrossRef PubMed
94. Pereg, Y., Lam, S., Teunisse, A., Biton, S., Meulmeester, E., Mittelman, L., Buscemi, G., Okamoto, K., Taya, Y., Shiloh, Y. and Jochemsen, A.G. (2005) Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. U.S.A. 102, 5056-5061 CrossRef PubMed
95. Linares, L.K., Kiernan, R., Triboulet, R., Chable-Bessia, C., Latreille, D., Cuvier, O., Lacroix, M., Le Cam, L., Coux, O. and Benkirane, M. (2007) Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat. Cell Biol. 9, 331-338 CrossRef PubMed
96. Kruse, J.P. and Gu, W. (2009) Modes of p53 regulation. Cell 137, 609-622 CrossRef PubMed
97. Cross, B., Chen, L., Cheng, Q., Li, B., Yuan, Z.M. and Chen, J. (2011) Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. J. Biol. Chem. 286, 16018-16029 CrossRef PubMed
98. Carter, S., Bischof, O., Dejean, A. and Vousden, K.H. (2007) C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 9, 428-435 CrossRef PubMed
99. Lohrum, M.A., Woods, D.B., Ludwig, R.L., Balint, E. and Vousden, K.H. (2001) C-terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell. Biol. 21, 8521-8532 CrossRef PubMed
100. Ofir-Rosenfeld, Y., Boggs, K., Michael, D., Kastan, M.B. and Oren, M. (2008) Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol. Cell 32, 180-189 CrossRef PubMed
101. Love, I.M. and Grossman, S.R. (2012) It takes 15 to tango: making sense of the many ubiquitin ligases of p53. Genes Cancer 3, 249-263 CrossRef PubMed
102. Harris, S.L. and Levine, A.J. (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908 CrossRef PubMed
103. Bouska, A. and Eischen, C.M. (2009) Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem. Sci. 34, 279-286 CrossRef PubMed
104. Reed, S.M. and Quelle, D.E. (2014) p53 acetylation: regulation and consequences. Cancers 7, 30-69 CrossRef PubMed
105. Jenkins, L.M., Durell, S.R., Mazur, S.J. and Appella, E. (2012) p53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis 33, 1441-1449 CrossRef PubMed
106. MacLaine, N.J. and Hupp, T.R. (2011) How phosphorylation controls p53. Cell Cycle 10, 916-921 CrossRef PubMed
107. Meek, D.W. (2009) Tumour suppression by p53: a role for the DNA damage response? Nat. Rev. Cancer 9, 714-723
108. Meek, D.W. and Anderson, C.W. (2009) Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb. Perspect. Biol. 1, a000950 CrossRef PubMed
109. Dehart, C.J., Chahal, J.S., Flint, S.J. and Perlman, D.H. (2014) Extensive post-translational modification of active and inactivated forms of endogenous p53. Mol. Cell. Proteomics 13, 1-17 CrossRef PubMed
110. Feng, J., Tamaskovic, R., Yang, Z., Brazil, D.P., Merlo, A., Hess, D. and Hemmings, B.A. (2004) Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J. Biol. Chem. 279, 35510-35517 CrossRef PubMed
111. Francoz, S., Froment, P., Bogaerts, S., De Clercq, S., Maetens, M., Doumont, G., Bellefroid, E. and Marine, J.C. (2006) Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 3232-3237 CrossRef PubMed
112. Li, M., Brooks, C.L., Kon, N. and Gu, W. (2004) A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13, 879-886 CrossRef PubMed
113. Meulmeester, E., Maurice, M.M., Boutell, C., Teunisse, A.F., Ovaa, H., Abraham, T.E., Dirks, R.W. and Jochemsen, A.G. (2005) Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol. Cell 18, 565-576 CrossRef PubMed
114. Tang, J., Qu, L.K., Zhang, J., Wang, W., Michaelson, J.S., Degenhardt, Y.Y., El-Deiry, W.S. and Yang, X. (2006) Critical role for Daxx in regulating Mdm2. Nat. Cell Biol. 8, 855-862 CrossRef PubMed
115. Toledo, F., Krummel, K.A., Lee, C.J., Liu, C.W., Rodewald, L.W., Tang, M. and Wahl, G.M. (2006) A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9, 273-285 CrossRef PubMed
116. Toledo, F. and Wahl, G.M. (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6, 909-923 CrossRef PubMed
117. Cheng, Q., Song, T., Chen, L. and Chen, J. (2014) Autoactivation of the MDM2 E3 ligase by intramolecular interaction. Mol. Cell. Biol. 34, 2800-2810 CrossRef PubMed
118. Li, X., Gilkes, D., Li, B., Cheng, Q., Pernazza, D., Lawrence, H., Lawrence, N. and Chen, J. (2012) Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene 31, 3721-3732 CrossRef PubMed
119. Rocha, S., Campbell, K.J. and Perkins, N.D. (2003) p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. Mol. Cell 12, 15-25 CrossRef PubMed
120. ARF. Cell 91, 649-659 CrossRef PubMed
121. Sherr, C.J. (2006) Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6, 663-673 CrossRef PubMed
122. Miliani de Marval, P.L. and Zhang, Y. (2011) The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget 2, 234-238 PubMed
123. Schmidt, E.V. (2004) The role of c-myc in regulation of translation initiation. Oncogene 23, 3217-3221 CrossRef PubMed
124. Macias, E., Jin, A., Deisenroth, C., Bhat, K., Mao, H., Lindstrom, M.S. and Zhang, Y. (2010) An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 interaction. Cancer Cell 18, 231-243 CrossRef PubMed
125. Pan, W., Issaq, S. and Zhang, Y. (2011) The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression. PLoS One 6, e21625 CrossRef PubMed
126. Cheok, C.F., Verma, C.S., Baselga, J. and Lane, D.P. (2011) Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 8, 25-37 CrossRef PubMed
127. Shangary, S. and Wang, S. (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 49, 223-241 CrossRef PubMed
128. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C. et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 CrossRef PubMed
129. Gayther, S.A., Batley, S.J., Linger, L., Bannister, A., Thorpe, K., Chin, S.F., Daigo, Y., Russell, P., Wilson, A., Sowter, H.M. et al. (2000) Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24, 300-303 CrossRef PubMed
130. Huang, W.C., Ju, T.K., Hung, M.C. and Chen, C.C. (2007) Phosphorylation of CBP by IKKα promotes cell growth by switching the binding preference of CBP from p53 to NF-κB. Mol. Cell 26, 75-87 CrossRef PubMed
131. Loughery, J., Cox, M., Smith, L.M. and Meek, D.W. (2014) Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Nucleic Acids Res. 42, 7666-7680 CrossRef PubMed
132. Cheok, C.F. and Lane, D.P. (2012) Seeking synergy in p53 transcriptional activation for cancer therapy. Discov. Med. 14, 263-271 PubMed
133. Li, Y.C. and Wahl, G.M. (2012) What a difference a phosphate makes: life or death decided by a single amino acid in MDM2. Cancer Cell 21, 595-596 CrossRef PubMed
134. 394regulates the amplitude and duration of the DNA damage response in mice. Cancer Cell 21, 668-679 CrossRef PubMed
135. Maya, R., Balass, M., Kim, S.T., Shkedy, D., Leal, J.F., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y. et al. (2001) ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15, 1067-1077 CrossRef PubMed
136. Cheng, Q., Chen, L., Li, Z., Lane, W.S. and Chen, J. (2009) ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J. 28, 3857-3867 CrossRef PubMed
137. Shinozaki, T., Nota, A., Taya, Y. and Okamoto, K. (2003) Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export. Oncogene 22, 8870-8880 CrossRef PubMed
138. Cheng, Q., Cross, B., Li, B., Chen, L., Li, Z. and Chen, J. (2011) Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage. Mol. Cell. Biol. 31, 4951-4963 CrossRef PubMed
139. Goldberg, Z., Sionov, R.V., Berger, M., Zwang, Y., Perets, R., Van Etten, R.A., Oren, M., Taya, Y. and Haupt, Y. (2002) Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J. 21, 3715-3727 CrossRef PubMed
140. Mayo, L.D. and Donner, D.B. (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U.S.A. 98, 11598-11603 CrossRef PubMed
141. Zhou, B.P., Liao, Y., Xia, W., Zou, Y., Spohn, B. and Hung, M.C. (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3, 973-982 CrossRef PubMed
142. Feng, Z., Liu, L., Zhang, C., Zheng, T., Wang, J., Lin, M., Zhao, Y., Wang, X., Levine, A.J. and Hu, W. (2012) Chronic restraint stress attenuates p53 function and promotes tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 109, 7013-7018 CrossRef PubMed
143. Bond, G.L., Hu, W., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P. et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 CrossRef PubMed
144. Blattner, C., Hay, T.J., Meek, D.W. and Lane, D.P. (2002) Hypophosphorylation of Mdm2 augments p53 stability. Mol. Cell. Biol. 22, 6170-6182 CrossRef PubMed
145. Hay, T.J. and Meek, D.W. (2000) Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett. 478, 183-186 CrossRef PubMed
146. Hjerrild, M., Milne, D., Dumaz, N., Hay, T., Issinger, O.G. and Meek, D. (2001) Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells. Biochem. J. 355, 347-356 CrossRef PubMed
147. Boehme, K.A., Kulikov, R. and Blattner, C. (2008) p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc. Natl. Acad. Sci. U.S.A. 105, 7785-7790 CrossRef PubMed
148. Kulikov, R., Boehme, K.A. and Blattner, C. (2005) Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol. Cell. Biol. 25, 7170-7180 CrossRef PubMed
149. Winter, M., Milne, D., Dias, S., Kulikov, R., Knippschild, U., Blattner, C. and Meek, D. (2004) Protein kinase CK1-δ phosphorylates key sites in the acidic domain of Mdm2 that regulate p53 turnover. Biochemistry 43, 16356-16364 CrossRef PubMed
150. Bozulic, L., Surucu, B., Hynx, D. and Hemmings, B.A. (2008) PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol. Cell 30, 203-213 CrossRef PubMed
151. Surucu, B., Bozulic, L., Hynx, D., Parcellier, A. and Hemmings, B.A. (2008) In vivo analysis of PKB/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J. Biol. Chem. 283, 30025-30033 CrossRef PubMed
152. Jin, Y., Dai, M.S., Lu, S.Z., Xu, Y., Luo, Z., Zhao, Y. and Lu, H. (2006) 14-3-3γ binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. EMBO J. 25, 1207-1218 CrossRef PubMed
153. LeBron, C., Chen, L., Gilkes, D.M. and Chen, J. (2006) Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J. 25, 1196-1206 CrossRef PubMed
154. Okamoto, K., Kashima, K., Pereg, Y., Ishida, M., Yamazaki, S., Nota, A., Teunisse, A., Migliorini, D., Kitabayashi, I., Marine, J.C. et al. (2005) DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol. Cell. Biol. 25, 9608-9620 CrossRef PubMed
155. Pereg, Y., Lam, S., Teunisse, A., Biton, S., Meulmeester, E., Mittelman, L., Buscemi, G., Okamoto, K., Taya, Y., Shiloh, Y. and Jochemsen, A.G. (2006) Differential roles of ATM-and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol. Cell. Biol. 26, 6819-6831 CrossRef PubMed
156. Wang, Y.V., Leblanc, M., Wade, M., Jochemsen, A.G. and Wahl, G.M. (2009) Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell 16, 33-43 CrossRef PubMed
157. Zuckerman, V., Lenos, K., Popowicz, G.M., Silberman, I., Grossman, T., Marine, J.C., Holak, T.A., Jochemsen, A.G. and Haupt, Y. (2009) c-Abl phosphorylates Hdmx and regulates its interaction with p53. J. Biol. Chem. 284, 4031-4039 CrossRef PubMed
158. Khoronenkova, S.V., Dianova, II, Ternette, N., Kessler, B.M., Parsons, J.L. and Dianov, G.L. (2012) ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol. Cell 45, 801-813 CrossRef PubMed
159. 46, in response to ionizing radiation. J. Biol. Chem. 277, 12491-12494 CrossRef PubMed
160. 18that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem. J. 342, 133-141 CrossRef PubMed
161. Dumaz, N., Milne, D.M. and Meek, D.W. (1999) Protein kinase CK1 is a p53 threonine-18 protein kinase which requires prior phosphorylation of serine 15. FEBS Lett. 463, 312-316 CrossRef PubMed
162. Feng, H., Jenkins, L.M., Durell, S.R., Hayashi, R., Mazur, S.J., Cherry, S., Tropea, J.E., Miller, M., Wlodawer, A., Appella, E. and Bai, Y. (2009) Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure 17, 202-210 CrossRef PubMed
163. Ferreon, J.C., Lee, C.W., Arai, M., Martinez-Yamout, M.A., Dyson, H.J. and Wright, P.E. (2009) Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2. Proc. Natl. Acad. Sci. U.S.A. 106, 6591-6596 CrossRef PubMed
164. Lee, C.W., Ferreon, J.C., Ferreon, A.C., Arai, M. and Wright, P.E. (2010) Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 107, 19290-19295 CrossRef PubMed
165. Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C.W. and Appella, E. (2000) Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase: effect on Mdm2 binding. J. Biol. Chem. 275, 9278-9283 CrossRef PubMed
166. Teufel, D.P., Bycroft, M. and Fersht, A.R. (2009) Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene 28, 2112-2118 CrossRef PubMed
167. Brown, C.J., Srinivasan, D., Jun, L.H., Coomber, D., Verma, C.S. and Lane, D.P. (2008) The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides. Cell Cycle 7, 608-610 CrossRef PubMed
168. Lee, H.S., Hauber, S.O., Vindus, D. and Niemeyer, M. (2008) Isostructural potassium and thallium salts of sterically crowded triazenes: a structural and computational study. Inorg. Chem. 47, 4401-4412 CrossRef PubMed
169. ElSawy, K.M., Sim, A., Lane, D.P., Verma, C.S. and Caves, L.S. (2015) A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2. Cell Cycle 14, 179-188 CrossRef PubMed
170. Zhang, Y. and Xiong, Y. (2001) A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 292, 1910-1915 CrossRef PubMed
171. Dumaz, N., Milne, D.M., Jardine, L.J. and Meek, D.W. (2001) Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochem. J. 359, 459-464 CrossRef PubMed
172. Jabbur, J.R. and Zhang, W. (2002) p53 antiproliferative function is enhanced by aspartate substitution at threonine 18 and serine 20. Cancer Biol. Ther. 1, 277-283 CrossRef PubMed
173. MacPherson, D., Kim, J., Kim, T., Rhee, B.K., Van Oostrom, C.T., DiTullio, R.A., Venere, M., Halazonetis, T.D., Bronson, R., De Vries, A. et al. (2004) Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 23, 3689-3699 CrossRef PubMed
174. Sakaguchi, K., Herrera, J.E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C.W. and Appella, E. (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831-2841 CrossRef PubMed
175. Teufel, D.P., Freund, S.M., Bycroft, M. and Fersht, A.R. (2007) Four domains of p300 each bind tightly to a sequence spanning both transactivation domains of p53. Proc. Natl. Acad. Sci. U.S.A. 104, 7009-7014 CrossRef PubMed
176. Jenkins, L.M., Yamaguchi, H., Hayashi, R., Cherry, S., Tropea, J.E., Miller, M., Wlodawer, A., Appella, E. and Mazur, S.J. (2009) Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry 48, 1244-1255 CrossRef PubMed
177. Lee, C.W., Martinez-Yamout, M.A., Dyson, H.J. and Wright, P.E. (2010) Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. Biochemistry 49, 9964-9971 CrossRef PubMed
178. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. and Gu, W. (2008) Acetylation is indispensable for p53 activation. Cell 133, 612-626 CrossRef PubMed
179. Espinosa, J.M. and Emerson, B.M. (2001) Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8, 57-69 CrossRef PubMed
180. Li, M., Luo, J., Brooks, C.L. and Gu, W. (2002) Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277, 50607-50611 CrossRef PubMed
181. Barlev, N.A., Liu, L., Chehab, N.H., Mansfield, K., Harris, K.G., Halazonetis, T.D. and Berger, S.L. (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8, 1243-1254 CrossRef PubMed
182. Liu, L., Scolnick, D.M., Trievel, R.C., Zhang, H.B., Marmorstein, R., Halazonetis, T.D. and Berger, S.L. (1999) p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19, 1202-1209 PubMed
183. Knights, C.D., Catania, J., Di Giovanni, S., Muratoglu, S., Perez, R., Swartzbeck, A., Quong, A.A., Zhang, X., Beerman, T., Pestell, R.G. and Avantaggiati, M.L. (2006) Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 173, 533-544 CrossRef PubMed
184. Chao, C., Wu, Z., Mazur, S.J., Borges, H., Rossi, M., Lin, T., Wang, J.Y., Anderson, C.W., Appella, E. and Xu, Y. (2006) Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 26, 6859-6869 CrossRef PubMed
185. Sykes, S.M., Mellert, H.S., Holbert, M.A., Li, K., Marmorstein, R., Lane, W.S. and McMahon, S.B. (2006) Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 24, 841-851 CrossRef PubMed
186. Tang, Y., Luo, J., Zhang, W. and Gu, W. (2006) Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 24, 827-839 CrossRef PubMed
187. Rocha, S., Martin, A.M., Meek, D.W. and Perkins, N.D. (2003) p53 represses cyclin D1 transcription through down-regulation of Bcl-3 and inducing increased association of the p52 NFκB subunit with histone deacetylase 1. Mol. Cell. Biol. 23, 4713-4727 CrossRef PubMed
188. Kruse, J.P. and Gu, W. (2008) SnapShot: p53 posttranslational modifications. Cell 133, 930 CrossRef PubMed
189. Loughery, J. and Meek, D.W. (2013) Switching on p53: an essential role for protein phosphorylation? Biodiscovery 8, 1
190. Nguyen, T.-A., Menendez, D., Resnick, M.A. and Anderson, C.W. (2014) Mutant TP53 posttranslational modifications: challenges and opportunities. Hum. Mutat. 35, 738-755 CrossRef PubMed
191. Berger, S.L. (2010) Keeping p53 in check: a high-stakes balancing act. Cell 142, 17-19 CrossRef PubMed
192. Hamamoto, R., Saloura, V. and Nakamura, Y. (2015) Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nat. Rev. Cancer 15, 110-124 CrossRef PubMed
193. Latonen, L., Taya, Y. and Laiho, M. (2001) UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts. Oncogene 20, 6784-6793 CrossRef PubMed
194. Saito, S., Yamaguchi, H., Higashimoto, Y., Chao, C., Xu, Y., Fornace, Jr, A.J., Appella, E. and Anderson, C.W. (2003) Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J. Biol. Chem. 278, 37536-37544 CrossRef PubMed
195. Espinosa, J.M. (2008) Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 27, 4013-4023 CrossRef PubMed
196. Murray-Zmijewski, F., Slee, E.A. and Lu, X. (2008) A complex barcode underlies the heterogeneous response of p53 to stress. Nat. Rev. Mol. Cell Biol. 9, 702-712 CrossRef PubMed
197. Lahav, G., Rosenfeld, N., Sigal, A., Geva-Zatorsky, N., Levine, A.J., Elowitz, M.B. and Alon, U. (2004) Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat. Genet. 36, 147-150 CrossRef PubMed
198. Le Guezennec, X. and Bulavin, D.V. (2010) WIP1 phosphatase at the crossroads of cancer and aging. Trends Biochem. Sci. 35, 109-114 CrossRef PubMed
199. Lu, X., Nannenga, B. and Donehower, L.A. (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 19, 1162-1174 CrossRef PubMed
200. Lu, X., Ma, O., Nguyen, T.A., Jones, S.N., Oren, M. and Donehower, L.A. (2007) The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12, 342-354 CrossRef PubMed
201. Cox, M.L. and Meek, D.W. (2010) Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. Cell. Signal. 22, 564-571 CrossRef PubMed
202. Espinosa, J.M., Verdun, R.E. and Emerson, B.M. (2003) p53 functions through stress-and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol. Cell 12, 1015-1027 CrossRef PubMed
203. Mellert, H., Sykes, S.M., Murphy, M.E. and McMahon, S.B. (2007) The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain. Cell Cycle 6, 1304-1306 CrossRef PubMed
204. van Leeuwen, I.M., Higgins, M., Campbell, J., McCarthy, A.R., Sachweh, M.C., Navarro, A.M. and Lain, S. (2013) Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2. Mol. Cancer Ther. 12, 471-480 CrossRef PubMed
205. Ito, A., Lai, C.H., Zhao, X., Saito, S., Hamilton, M.H., Appella, E. and Yao, T.P. (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20, 1331-1340 CrossRef PubMed
206. Velimezi, G., Liontos, M., Vougas, K., Roumeliotis, T., Bartkova, J., Sideridou, M., Dereli-Oz, A., Kocylowski, M., Pateras, I.S., Evangelou, K. et al. (2013) Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat. Cell Biol. 15, 967-977 CrossRef PubMed
207. Rocha, S., Garrett, M.D., Campbell, K.J., Schumm, K. and Perkins, N.D. (2005) Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. 24, 1157-1169 CrossRef PubMed
208. Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.V., Kolettas, E., Niforou, K., Zoumpourlis, V.C. et al. (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637 CrossRef PubMed
209. Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garrè, M., Nuciforo, P.G., Bensimon, A. et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638-642 CrossRef PubMed
210. Christophorou, M.A., Ringshausen, I., Finch, A.J., Swigart, L.B. and Evan, G.I. (2006) The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217 CrossRef PubMed
211. Hinkal, G., Parikh, N. and Donehower, L.A. (2009) Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One 4, e6654 CrossRef PubMed
212. Efeyan, A., Garcia-Cao, I., Herranz, D., Velasco-Miguel, S. and Serrano, M. (2006) Tumour biology: policing of oncogene activity by p53. Nature 443, 159 CrossRef PubMed
213. Efeyan, A., Murga, M., Martinez-Pastor, B., Ortega-Molina, A., Soria, R., Collado, M., Fernandez-Capetillo, O. and Serrano, M. (2009) Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS One 4, e5475 CrossRef PubMed
214. Bieging, K.T., Mello, S.S. and Attardi, L.D. (2014) Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359-370 CrossRef PubMed
215. Donehower, L.A. and Lozano, G. (2009) 20 years studying p53 functions in genetically engineered mice. Nat. Rev. Cancer 9, 831-841 CrossRef PubMed
216. Garcia, P.B. and Attardi, L.D. (2014) Illuminating p53 function in cancer with genetically engineered mouse models. Semin. Cell Dev. Biol. 27, 74-85 CrossRef PubMed
217. 18 phosphorylation in regulating p53 responses. J. Biol. Chem. 278, 41028-41033 CrossRef PubMed
218. Sluss, H.K., Armata, H., Gallant, J. and Jones, S.N. (2004) Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol. Cell. Biol. 24, 976-984 CrossRef PubMed
219. 23 and the response to DNA damage. Mol. Cell. Biol. 22, 2441-2449 CrossRef PubMed
220. Chao, C., Herr, D., Chun, J. and Xu, Y. (2006) Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J. 25, 2615-2622 PubMed
221. Liu, D., Ou, L., Clemenson, Jr, G.D., Chao, C., Lutske, M.E., Zambetti, G.P., Gage, F.H. and Xu, Y. (2010) Puma is required for p53-induced depletion of adult stem cells. Nat. Cell Biol. 12, 993-998 CrossRef PubMed
222. Ullrich, S.J., Sakaguchi, K., Lees-Miller, S.P., Fiscella, M., Mercer, W.E., Anderson, C.W. and Appella, E. (1993) Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. Proc. Natl. Acad. Sci. U.S.A. 90, 5954-5958 CrossRef PubMed
223. Bar, J.K., Slomska, I., Rabczynki, J., Noga, L. and Grybos, M. (2009) Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. Int. J. Gynecol. Cancer 19, 1322-1328 CrossRef PubMed
224. Furihata, M., Kurabayashl, A., Matsumoto, M., Sonobe, H., Ohtsuki, Y., Terao, N., Kuwahara, M. and Shuin, T. (2002) Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract. J. Pathol. 197, 82-88 CrossRef PubMed
225. Liu, C., Zhu, Y., Lou, W., Nadiminty, N., Chen, X., Zhou, Q., Shi, X.B., deVere White, R.W. and Gao, A.C. (2013) Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 73, 418-427 CrossRef PubMed
226. Matsumoto, M., Furihata, M., Kurabayashi, A. and Ohtsuki, Y. (2004) Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors. Oncol. Rep. 12, 1039-1043 PubMed
227. Matsumoto, M., Furihata, M., Kurabayashi, A., Sasaguri, S., Araki, K., Hayashi, H. and Ohtsuki, Y. (2004) Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma. Oncology 67, 143-150 CrossRef PubMed
228. Matsumoto, M., Furihata, M. and Ohtsuki, Y. (2006) Posttranslational phosphorylation of mutant p53 protein in tumor development. Med. Mol. Morphol. 39, 79-87 CrossRef PubMed
229. Melnikova, V.O., Santamaria, A.B., Bolshakov, S.V. and Ananthaswamy, H.N. (2003) Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase. Oncogene 22, 5958-5966 CrossRef PubMed
230. Minamoto, T., Buschmann, T., Habelhah, H., Matusevich, E., Tahara, H., Boerresen-Dale, A.L., Harris, C., Sidransky, D. and Ronai, Z. (2001) Distinct pattern of p53 phosphorylation in human tumors. Oncogene 20, 3341-3347 CrossRef PubMed
231. Ray, D., Murphy, K.R. and Gal, S. (2012) The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation. Cancer Biol. Ther. 13, 848-857 CrossRef PubMed
232. Valenti, F. et al. (2011) Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle 10, 4330-4340 CrossRef PubMed
233. Zerbini, L.F., Wang, Y., Correa, R.G., Cho, J.Y. and Libermann, T.A. (2005) Blockage of NF-κB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. Cell Cycle 4, 1247-1253 CrossRef PubMed
234. Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M.B., Guzzardo, V. et al. (2009) A mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 137, 87-98 CrossRef PubMed
235. Cordenonsi, M., Montagner, M., Adorno, M., Zacchigna, L., Martello, G., Mamidi, A., Soligo, S., Dupont, S. and Piccolo, S. (2007) Integration of TGF-β and Ras/MAPK signaling through p53 phosphorylation. Science 315, 840-843 CrossRef PubMed
236. Higashimoto, Y., Saito, S., Tong, X.H., Hong, A., Sakaguchi, K., Appella, E. and Anderson, C.W. (2000) Human p53 is phosphorylated on serines 6 and 9 in response to DNA damage-inducing agents. J. Biol. Chem. 275, 23199-23203 CrossRef PubMed
237. Knippschild, U., Milne, D.M., Campbell, L.E., DeMaggio, A.J., Christenson, E., Hoekstra, M.F. and Meek, D.W. (1997) p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1δ in response to topoisomerase-directed drugs. Oncogene 15, 1727-1736 CrossRef PubMed
238. Suh, Y.A., Post, S.M., Elizondo-Fraire, A.C., Maccio, D.R., Jackson, J.G., El-Naggar, A.K., Van Pelt, C., Terzian, T. and Lozano, G. (2011) Multiple stress signals activate mutant p53 in vivo. Cancer Res. 71, 7168-7175 CrossRef PubMed
239. 392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res. 64, 4749-4754 CrossRef PubMed
240. Jones, R.G., Plas, D.R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M.J. and Thompson, C.B. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283-293 CrossRef PubMed
241. Maddocks, O.D. and Vousden, K.H. (2011) Metabolic regulation by p53. J. Mol. Med. 89, 237-245 CrossRef PubMed
242. Armata, H.L., Golebiowski, D., Jung, D.Y., Ko, H.J., Kim,4, J.K. and Sluss, H.K. (2010) Requirement of the ATM/p53 tumor suppressor pathway for glucose homeostasis. Mol. Cell. Biol. 30, 5787-5794 CrossRef PubMed
243. d'Adda di Fagagna, F., Reaper, P.M., Clay-Farrace, L., Fiegler, H., Carr, P., Von Zglinicki, T., Saretzki, G., Carter, N.P. and Jackson, S.P. (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198 CrossRef PubMed
244. Khalil, H.S., Tummala, H. and Zhelev, N. (2012) ATM in focus: a damage sensor and cancer target. Biodiscovery 5, 1-59
245. Webley, K., Bond, J.A., Jones, C.J., Blaydes, J.P., Craig, A., Hupp, T. and Wynford-Thomas, D. (2000) Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol. Cell. Biol. 20, 2803-2808 CrossRef PubMed
246. Yang, C., Tang, X., Guo, X., Niikura, Y., Kitagawa, K., Cui, K., Wong, S.T., Fu, L. and Xu, B. (2011) Aurora-B mediated ATM serine 1403 phosphorylation is required for mitotic ATM activation and the spindle checkpoint. Mol. Cell 44, 597-608 CrossRef PubMed
247. Zhou, K., Bellenguez, C., Spencer, C.C., Bennett, A.J., Coleman, R.L., Tavendale, R., Hawley, S.A., Donnelly, L.A., Schofield, C., Groves, C.J. et al. (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 43, 117-120 CrossRef PubMed
248. Meek, D.W. (2000) The role of p53 in the response to mitotic spindle damage. Pathol. Biol. (Paris) 48, 246-254 PubMed
249. Colin, D.J., Hain, K.O., Allan, L.A. and Clarke, P.R. (2015) Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins. Open Biol. 5, 140156 CrossRef PubMed
250. Hayashi, M.T., Cesare, A.J., Fitzpatrick, J.A., Lazzerini-Denchi, E. and Karlseder, J. (2012) A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest. Nat. Struct. Mol. Biol. 19, 387-394 CrossRef PubMed
251. Imreh, G., Norberg, H.V., Imreh, S. and Zhivotovsky, B. (2011) Chromosomal breaks during mitotic catastrophe trigger γH2AX-ATM-p53-mediated apoptosis. J. Cell Sci. 124, 2951-2963 CrossRef PubMed
252. Orth, J.D., Loewer, A., Lahav, G. and Mitchison, T.J. (2012) Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Mol. Biol. Cell 23, 567-576 CrossRef PubMed
253. Soussi, T., Caron de Fromentel, C. and May, P. (1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5, 945-952 PubMed
254. Chen, J. (2012) The roles of MDM2 and MDMX phosphorylation in stress signaling to p53. Genes Cancer 3, 274-282 CrossRef PubMed
255. Meek, D.W. and Hupp, T.R. (2010) The regulation of MDM2 by multisite phosphorylation: opportunities for molecular-based intervention to target tumours? Semin. Cancer Biol. 20, 19-28 CrossRef
256. Bulavin, D.V., Saito, S., Hollander, M.C., Sakaguchi, K., Anderson, C.W., Appella, E. and Fornace, Jr, A.J. (1999) Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18, 6845-6854 CrossRef PubMed
257. 20 J. Biol. Chem. 276, 39115-39122 CrossRef PubMed
258. Serrano, M.A., Li, Z., Dangeti, M., Musich, P.R., Patrick, S., Roginskaya, M., Cartwright, B. and Zou, Y. (2013) DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene 32, 2452-2462 CrossRef PubMed
259. D'Orazi, G., Cecchinelli, B., Bruno, T., Manni, I., Higashimoto, Y., Saito, S., Gostissa, M., Coen, S., Marchetti, A., Del Sal, G. et al. (2002) Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4, 11-19 CrossRef PubMed
260. Di Lello, P., Jenkins, L.M., Jones, T.N., Nguyen, B.D., Hara, T., Yamaguchi, H., Dikeakos, J.D., Appella, E., Legault, P. and Omichinski, J.G. (2006) Structure of the Tfb1/p53 complex: insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol. Cell 22, 731-740 CrossRef PubMed
261. Di Lello, P., Miller Jenkins, L.M., Mas, C., Langlois, C., Malitskaya, E., Fradet-Turcotte, A., Archambault, J., Legault, P. and Omichinski, J.G. (2008) p53 and TFIIEα share a common binding site on the Tfb1/p62 subunit of TFIIH. Proc. Natl. Acad. Sci. U.S.A. 105, 106-111 CrossRef PubMed
262. Hofmann, T.G., Moller, A., Sirma, H., Zentgraf, H., Taya, Y., Droge, W., Will, H. and Schmitz, M.L. (2002) Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4, 1-10 CrossRef PubMed
263. 46 without Ser/Thr-Gln sequences. Mol. Cell. Biol. 30, 1620-1633 CrossRef PubMed
264. Mayo, L.D., Seo, Y.R., Jackson, M.W., Smith, M.L., Rivera Guzman, J., Korgaonkar, C.K. and Donner, D.B. (2005) Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J. Biol. Chem. 280, 25953-25959 CrossRef PubMed
265. Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y. and Taya, Y. (2000) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849-862 CrossRef PubMed
266. Okoshi, R., Ozaki, T., Yamamoto, H., Ando, K., Koida, N., Ono, S., Koda, T., Kamijo, T., Nakagawara, A. and Kizaki, H. (2008) Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J. Biol. Chem. 283, 3979-3987 CrossRef PubMed
267. Smeenk, L., van Heeringen, S.J., Koeppel, M., Gilbert, B., Janssen-Megens, E., Stunnenberg, H.G. and Lohrum, M. (2011) Role of p53 serine 46 in p53 target gene regulation. PLoS One 6, e17574 CrossRef PubMed
268. 46 phosphorylation in the apoptotic response to DNA damage. Mol. Cell 25, 725-738 CrossRef PubMed
269. 46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J. Biol. Chem. 281, 5734-5740 CrossRef PubMed
270. Cai, X. and Liu, X. (2008) Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc. Natl. Acad. Sci. U.S.A. 105, 16958-16963 CrossRef PubMed
271. Li, H.H., Li, A.G., Sheppard, H.M. and Liu, X. (2004) Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol. Cell 13, 867-878 CrossRef PubMed
272. Shouse, G.P., Cai, X. and Liu, X. (2008) Serine 15 phosphorylation of p53 directs its interaction with B56γ and the tumor suppressor activity of B56γ-specific protein phosphatase 2A. Mol. Cell. Biol. 28, 448-456 CrossRef PubMed
273. Berger, M., Stahl, N., Del Sal, G. and Haupt, Y. (2005) Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol. Cell. Biol. 25, 5380-5388 CrossRef PubMed
274. Bech-Otschir, D., Kraft, R., Huang, X., Henklein, P., Kapelari, B., Pollmann, C. and Dubiel, W. (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J. 20, 1630-1639 CrossRef PubMed
275. Liu, Q., Kaneko, S., Yang, L., Feldman, R.I., Nicosia, S.V., Chen, J. and Cheng, J.Q. (2004) Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J. Biol. Chem. 279, 52175-52182 CrossRef PubMed
276. 269 in vivo is linked to inactivation of p53 function. J. Biol. Chem. 285, 37762-37772 CrossRef PubMed
277. 269 induces a mutant conformation to p53. J. Biol. Chem. 285, 37773-37786 CrossRef PubMed
278. Bischoff, J.R., Friedman, P.N., Marshak, D.R., Prives, C. and Beach, D. (1990) Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Natl. Acad. Sci. U.S.A. 87, 4766-4770 CrossRef PubMed
279. 315 stimulates p53-dependent transcription. J. Biol. Chem. 14, 4699-4708 CrossRef
280. Qu, L., Huang, S., Baltzis, D., Rivas-Estilla, A.M., Pluquet, O., Hatzoglou, M., Koumenis, C., Taya, Y., Yoshimura, A. and Koromilas, A.E. (2004) Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3β. Genes Dev. 18, 261-277 CrossRef PubMed
281. 312 contributes to tumor suppression by p53 in vivo.Proc. Natl. Acad. Sci. U.S.A. 107, 19479-19484 CrossRef PubMed
282. Waterman, M.J.F., Stavridi, E.S., F., W.J.L. and Halazonetis, T.D. (1998) ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 19, 175-178 CrossRef PubMed
283. 389 phosphorylation in p53 affects the basal gene expression level of many p53-dependent genes and alters the biphasic response to UV exposure in mouse embryonic fibroblasts. Mol. Cell. Biol. 28, 1974-1987 CrossRef PubMed
284. 389 Mol. Cell. Biol. 24, 8884-8894 CrossRef PubMed
285. 389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. Cancer Res. 65, 3610-3616 CrossRef PubMed
286. Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. (1992) Regulation of the specific DNA binding function of p53. Cell 71, 875-886 CrossRef PubMed
287. Keller, D.M., Zeng, X., Wang, Y., Zhang, Q.H., Kapoor, M., Shu, H., Goodman, R., Lozano, G., Zhao, Y. and Lu, H. (2001) A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell 7, 283-292 CrossRef PubMed
288. Milne, D.M., Palmer, R.H. and Meek, D.W. (1992) Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. Nucleic Acids Res. 20, 5565-5570 CrossRef PubMed
289. Sakaguchi, K., Sakamoto, M., Lewis, M.S., Anderson, C.W., Erikson, J.W., Appella, E. and Xie, D. (1997) Phosphorylation of serine 392 stabilises the tetramer formation of tumor suppressor protein p53. Biochemistry 36, 10117-10124 CrossRef PubMed
290. Huang, J., Perez-Burgos, L., Placek, B.J., Sengupta, R., Richter, M., Dorsey, J.A., Kubicek, S., Opravil, S., Jenuwein, T. and Berger, S.L. (2006) Repression of p53 activity by Smyd2-mediated methylation. Nature 444, 629-632 CrossRef PubMed
291. Ivanov, G.S., Ivanova, T., Kurash, J., Ivanov, A., Chuikov, S., Gizatullin, F., Herrera-Medina, E.M., Rauscher, 3rd, F., Reinberg, D. and Barlev, N.A. (2007) Methylation-acetylation interplay activates p53 in response to DNA damage. Mol. Cell. Biol. 27, 6756-6769 CrossRef PubMed
292. Kurash, J.K., Lei, H., Shen, Q., Marston, W.L., Granda, B.W., Fan, H., Wall, D., Li, E. and Gaudet, F. (2008) Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol. Cell 29, 392-400 CrossRef PubMed
293. Kachirskaia, I., Shi, X., Yamaguchi, H., Tanoue, K., Wen, H., Wang, E.W., Appella, E. and Gozani, O. (2008) Role for 53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling. J. Biol. Chem. 283, 34660-34666 CrossRef PubMed
294. Shi, X., Kachirskaia, I., Yamaguchi, H., West, L.E., Wen, H., Wang, E.W., Dutta, S., Appella, E. and Gozani, O. (2007) Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 27, 636-646 CrossRef PubMed
295. West, L.E., Roy, S., Lachmi-Weiner, K., Hayashi, R., Shi, X., Appella, E., Kutateladze, T.G. and Gozani, O. (2010) The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. J. Biol. Chem. 285, 37725-37732 CrossRef PubMed